BioPharma Resources

Free tool

PDUFA calendar

FDA does not publish its target action dates; companies announce them. This calendar is compiled each week by Claude from press releases, filings, FDA's advisory committee calendar and trade press, and every row links the page that states the date. Dates move, and many small companies never announce one, so treat it as a starting point.

Last checked: Nov 19, 2026Source: Company announcements, FDA advisory committee calendarMethods & limitations

This week's calendar

Compiled by Claude (Anthropic's AI) with web searches, once a week.

Decided recently

Original approvals, plus supplements under breakthrough therapy or accelerated approval, from Drugs@FDA.

  • Klygefa approved · Alexion Pharm NovelOrphanNov 13, 2026
  • Pebrilzo approved · Biocon Biologics INC Nov 12, 2026
  • Pimjetmi approved · Emd Serono NovelNov 10, 2026
  • Oxderys approved · Avyxa Holdings Nov 9, 2026
  • Multibic approved · Fresenius Medical Care Renal Therapies Group LLC Nov 9, 2026
  • Sunharbo approved · Bayer Healthcare NovelPriority reviewNov 9, 2026
  • Axycis approved · Avyxa Holdings Oct 29, 2026
  • Lucamzi approved · Xbrane Biopharma Ab Oct 27, 2026
  • Enzeevu approved · Sandoz INC Oct 22, 2026
  • Ahzantive approved · Formycon AG Oct 22, 2026
  • Pavblu approved · Amgen INC Oct 22, 2026
  • Hibsago approved · Glaxosmithkline NovelPriority reviewOct 20, 2026

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.